Jazz Pharmaceuticals Offers HAL Study Data On JZP-110

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) presented new data from a Human Abuse Liability (HAL) study on its investigational wake-promoting agent, JZP-110, at the annual meeting of the Associated Professional Sleep Societies (APSS).

JZP-110 is currently in phase III development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).

The randomized, double-blinded, placebo-controlled, six-sequence crossover study evaluated the abuse potential of JZP-110, relative to the Schedule IV stimulant phentermine, in adults with a recent history of recreational polydrug use, including stimulants.

Subjects were randomized in the six-test sequences, and they received a single treatment that included JZP-110 at 300 mg, 600 mg and 1200 mg; phentermine at 45 mg and 90 mg; and placebo, with a two-day washout period between each treatment.

The primary endpoint of the study was Liking at the Moment across the first 12 hours after drug administration, while the key secondary endpoints was Overall Next Day Drug Liking and willingness to Take the Drug Again at 24 hours after drug administration.

Results from the study demonstrated that each dose of JZP-110 had consistently lower ratings on both the primary and the secondary endpoints, compared to the Schedule IV stimulant phentermine (90 mg).

However, JZP-110 (300 mg) and JZP-110 (600 mg and at 1200 mg) did not have any statistical difference in the Overall Next Day Drug Liking measure, compared to phentermine (45 mg) and placebo, respectively.

We note that JZP-110 has Orphan Drug designation in the U.S. for narcolepsy.

We remind investors that in Jan 2014, Jazz acquired worldwide development, manufacturing and commercial rights to JZP-110 from Aerial BioPharma.

Jazz currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Bristol-Myers Squibb Company (NYSE:BMY) , ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) and Pfizer Inc. (NYSE:PFE) , each sporting a Zacks Rank #1 (Strong Buy).

BRISTOL-MYERS (BMY): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research